Indeed, HER2 blockade with afatinib, lapatinib, or trastuzumab did not demonstrate any antitumor efficacy in two METN375S-positive patient-derived xenografts (PDX) of hepatocellular carcinoma (HCC) (Supplementary Fig. 9D–G), in which phosphorylations of MET and HER2 were not prominent in the tumors (Supplementary Fig. 9H, I). Here, ERBB2 is linked to hepatocellular carcinoma.